{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:12:19Z","timestamp":1790079139725,"version":"4.0.1"},"reference-count":20,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematol. Rep.","Hematology Reports"],"abstract":"<jats:p>Background and Clinical Relevance: The association between acute myeloid leukemia (AML) and monoclonal gammopathy of undetermined significance (MGUS) is rare and likely coincidental, due to the similar epidemiology of these two blood disorders in older AML patients who are not eligible for intensive chemotherapy or aggressive treatment, as they can be excessively myelosuppressive. Such treatments include those containing venetoclax, an easy-to-use all-oral form of decitabine\u2013cedazuridine (DEC-C), which is now available and approved for AML in addition to standard parenteral DNA methyltransferase inhibitors, which have been commonly used in routine clinical practice for about two decades in patients unsuitable for intensive chemotherapy (IC). Case Presentation: A 71-year-old woman developed a therapy-related acute myeloid leukemia (t-AML) seven years after the discovery of the plasma cell dyscrasia. She had carried an asymptomatic and non-progressing IgG-\u03bb MGUS since 2019 while affected by breast cancer, which was cured with chemotherapy and radiotherapy. BM smear and trephine biopsy at the time of t-AML diagnosis showed 30% myelomonoblasts and 8% plasma cells, while SPEP showed the presence of 15 g\/L of monoclonal protein. However, considering her age and other medical and personal history, the patient was found unsuitable for IC as well as venetoclax treatment because of the myelosuppressive effect of the therapy. Therefore, she received DEC-C oral monotherapy. After four DEC-C cycles, she achieved CR with hematological incomplete recovery (CRi). During DEC-C monotherapy, serum immunofixation (IF) and BM evaluations after 12 months of treatment showed gradual clearance of the IgG-\u03bb paraprotein and BM plasma cells. Maintenance therapy with oral DEC-C is ongoing for 18 months after achieving CRi, without any signs of toxicity or infection. Conclusions: This report describes the first anecdotal case of t-AML responding to DEC-C with concomitant clearance of the paraprotein associated with MGUS.<\/jats:p>","DOI":"10.3390\/hematolrep18050066","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:21:48Z","timestamp":1790072508000},"page":"66","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Concurrent Remission of Therapy-Related Acute Myeloid Leukemia and IgG-\u03bb MGUS During Oral Decitabine\u2013Cedazuridine: A Case Report"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2226-6518","authenticated-orcid":false,"given":"Pasquale","family":"Niscola","sequence":"first","affiliation":[{"name":"Hematology Unit, Medical Area Department, S. Eugenio Hospital (ASL Roma 2), 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Mazzone","sequence":"additional","affiliation":[{"name":"Hematology Unit, Medical Area Department, S. Eugenio Hospital (ASL Roma 2), 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Giovannini","sequence":"additional","affiliation":[{"name":"Hematology Unit, Medical Area Department, S. Eugenio Hospital (ASL Roma 2), 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Gianfelici","sequence":"additional","affiliation":[{"name":"Hematology Unit, Medical Area Department, S. Eugenio Hospital (ASL Roma 2), 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3958-0669","authenticated-orcid":false,"given":"Maria Ilaria","family":"Del Principe","sequence":"additional","affiliation":[{"name":"Hematology Unit, Medical Area Department, S. Eugenio Hospital (ASL Roma 2), 00144 Rome, Italy"},{"name":"Hematology, Department of Biomedicine and Prevention, University of Tor Vergata Rome, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"key":"ref_1","first-page":"553","article-title":"Effective Treatment with Venetoclax and Hypomethylating Agents for Coexisting Multiple Myeloma and Acute Myeloid Leukemia: A Case Report and Literature Review","volume":"54","author":"Chen","year":"2024","journal-title":"Ann. Clin. Lab. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cancergen.2023.12.005","article-title":"Simultaneous occurrence of multiple myeloma and acute myeloid leukemia: Case report and literature review","volume":"282\u2013283","author":"Li","year":"2024","journal-title":"Cancer Genet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3892\/ol.2025.14970","article-title":"Coexistence of acute myeloid leukemia with a complex chromosomal translocation and monoclonal gammopathy of undetermined significance: A case report and literature review","volume":"29","author":"Qiao","year":"2025","journal-title":"Oncol. Lett."},{"key":"ref_4","first-page":"e83730","article-title":"Synchronous Occurrence of Acute Myeloid Leukemia and Multiple Myeloma: A Case Report and Literature Review","volume":"17","author":"Musbau","year":"2025","journal-title":"Cureus"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/blood.2024026236","article-title":"Clonal hematopoiesis is clonally unrelated to multiple myeloma and is associated with specific microenvironmental changes","volume":"146","author":"Lionetti","year":"2025","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e00270","DOI":"10.1097\/BS9.0000000000000270","article-title":"The tumor microenvironment in hematologic malignancies: Immune evasion, metabolic reprogramming, and therapeutic resistance","volume":"8","author":"Walid","year":"2026","journal-title":"Blood Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41392-023-01342-6","article-title":"Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Ilic, J., Bold, A., and Knop, S. (2026). The role of epigenetic modifications in hematological cancers. Front. Oncol., 16.","DOI":"10.3389\/fonc.2026.1744018"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s10238-025-01972-w","article-title":"Beyond the DNA sequence: Mapping the dynamic epigenetic landscape for risk stratification and therapeutic intervention in acute myeloid leukemia","volume":"26","author":"Xie","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Caprio, C., Sacco, A., Giustini, V., and Roccaro, A.M. (2020). Epigenetic Aberrations in Multiple Myeloma. Cancers, 12.","DOI":"10.3390\/cancers12102996"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"595435","DOI":"10.2147\/OTT.S595435","article-title":"The Role of Genomics in the Development and Treatment of Multiple Myeloma: Understanding the Challenges and Opportunities","volume":"19","author":"Ren","year":"2026","journal-title":"OncoTargets Ther."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Niscola, P., Gianfelici, V., Giovannini, M., Mazzone, C., and Del Principe, M.I. (2026). Evolving Management Approaches Toward Personalized Therapy in Acute Myeloid Leukemia: A Narrative Review. J. Pers. Med., 16.","DOI":"10.3390\/jpm16050266"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1080\/14737140.2025.2544859","article-title":"Oral decitabine and cedazuridine for the treatment of myelodysplastic syndromes: An integrated review of clinical, economic and patient-centered evidence","volume":"25","author":"Zeidan","year":"2025","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000485960","article-title":"Monoclonal Gammopathy Responsive to Decitabine Given for Acute Myeloid Leukemia in a Frail Patient","volume":"139","author":"Niscola","year":"2018","journal-title":"Acta Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/leu.2013.34","article-title":"Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): A population-based study of 17,315 patients","volume":"27","author":"Roeker","year":"2013","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s00277-015-2431-y","article-title":"Chronic myelomonocytic leukemia coexisting with monoclonal gammopathy: Concomitant response to azacitidine of both disorders","volume":"94","author":"Niscola","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e45190","DOI":"10.1097\/MD.0000000000045190","article-title":"A case of acute myeloid leukemia and multiple myeloma is observed to occur simultaneously","volume":"104","author":"Hao","year":"2025","journal-title":"Medicine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/j.seminhematol.2020.12.004","article-title":"DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma","volume":"58","author":"Khouri","year":"2021","journal-title":"Semin. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00277-017-3032-8","article-title":"Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation","volume":"96","author":"Oka","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"31568","DOI":"10.1038\/s41598-025-17093-z","article-title":"Combinatorial DNMTs and EZH2 inhibition reprograms the H3K27me3 and DNAme-mediated onco-epigenome to suppress multiple myeloma proliferation","volume":"15","author":"Nylund","year":"2025","journal-title":"Sci. Rep."}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/5\/66\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:38:16Z","timestamp":1790077096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/5\/66"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":20,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["hematolrep18050066"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep18050066","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]}}}